HR 2580 — Modernizing Drug Enforcement Act of 2019
Last action — Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
-
✓Introduced
-
2In Committee
-
3Passed House
-
4Passed Senate
-
5To Executive
-
6Enacted
This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
This bill is no longer active — its legislative session has ended, so there are no live odds of enactment. It would have to be reintroduced in the current session to move again.
In plain language
The bill modifies drug scheduling for mu opioid receptor agonists.
This bill amends the Controlled Substances Act to classify mu opioid receptor agonists as Schedule I substances, with exceptions for specific medical uses. It requires the Attorney General to update the scheduling within 180 days of enactment.
Summary
Modernizing Drug Enforcement Act of 2019 This bill deems a drug or substance that acts as an opioid mu receptor agonist (e.g., morphine) to be in schedule I of the Controlled Substances Act, subject to certain exceptions. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.
Bill Text
- Introduced Introduced in House Current html May 08, 2019
Compared against current U.S. Code AI-generated reading aid — verify against the official bill.
The bill amends the Controlled Substances Act to classify mu opioid receptor agonists as substances in schedule I, with specific exceptions for legitimate medical or research use.
-
21 U.S.C. 802
(18)(A) The term `opiate' or `opioid'-- (i) means any drug or other substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability; and (ii) includes any drug or other substance that acts as a mu opioid receptor agonist. (B) The term `mu opioid receptor' is a molecule that when bound to, and activated by, a mu opioid receptor agonist would result in analgesia, euphoria, addiction, or respiratory depression in the central nervous system. (C) The term `mu opioid receptor agonist' is a substance that when bound to, and interacting with, the mu opioid receptor, activates the receptor to result in analgesia, euphoria, addiction, or respiratory depression.
New definitions are established for 'opiate' or 'opioid' and 'mu opioid receptor agonist', focusing on the classification of drugs that act on mu opioid receptors.
-
21 U.S.C. 811
(k) Mu Opioid Receptor Agonists.-- (1) In general.--Effective as of the date of enactment of the Modernizing Drug Enforcement Act of 2019, schedule I under section 202 is deemed to include, unless specifically exempted or unless listed in another schedule, any chemical substances, including their salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, that act as mu opioid receptor agonists, and any material, compound, mixture, or preparation that contains any quantity of such substances.
Mu opioid receptor agonists are explicitly added to schedule I of controlled substances, broadening the scope of substances classified under strict regulations.
-
21 U.S.C. 811
(2) Exceptions.--A chemical substance is exempt from inclusion in schedule I by operation of paragraph (1)-- (A) if the substance is the subject of an approved application submitted under subsection (b) or (j) of section 505 of the Federal Food, Drug, and Cosmetic Act; (B) to the extent the substance is exempt from the provisions of section 505 of such Act relating to new drugs because-- (i) the substance is intended solely for investigational use as described in section 505(i) of such Act; and (ii) the substance is being used exclusively for purposes of a clinical trial that is the subject of an effective investigational new drug application; or (C) to the extent the substance is the subject of a nonclinical study by researchers qualified by scientific training to investigate the safety and effectiveness of drugs.
Conditions are defined under which mu opioid receptor agonists can be exempt from schedule I restrictions, enabling legitimate medical and research applications.
-
21 U.S.C. 811
(3) Listing.--Not later than 180 days after the date of enactment of the Modernizing Drug Enforcement Act of 2019, the Attorney General shall update schedule I in accordance with paragraph (1). The Attorney General may list substances in schedule I pursuant to paragraph (1) without regard to the process and considerations that are otherwise applicable under this section for adding, removing, or transferring controlled substances to, from, or among the schedules under section 202.
The Attorney General is required to update schedule I to include mu opioid receptor agonists, bypassing usual procedural requirements.
Action History
-
Introduced in House
-
Introduced in House
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Referred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
-
Referred to the Subcommittee on Health.
-
Referred to the Subcommittee on Crime, Terrorism, and Homeland Security.
Sponsors
- David P. Roe · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 546 not signed on
Sponsors (1)
- Roe, David P. Republican
Co-sponsors (0)
None.
Not signed on (546)
546 members have not signed on to this bill.
Show all 546 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Subjects
Frequently asked questions
- What does HR 2580 do?
- Modernizing Drug Enforcement Act of 2019 This bill deems a drug or substance that acts as an opioid mu receptor agonist (e.g., morphine) to be in schedule I of the Controlled Substances Act, subject to certain exceptions. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.
- Who sponsors HR 2580?
- HR 2580 is sponsored by Roe, David P. (Republican).
- What is the current status of HR 2580?
- This bill died with 116th Congress. It reached “In Committee” and never advanced before the session ended, so it can no longer move — a new version would have to be reintroduced in the current session.
- Where can I track HR 2580?
- Track HR 2580 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on HR 2580
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of HR 2580
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →